Impact Biomedical Inc. Form 8-K Summary
Business Context and Reporting Period
Impact Biomedical Inc. filed a Form 8-K dated June 6, 2024, reporting changes to its board of directors under Item 5.02. The filing is not a periodic financial report and does not provide financial statements or operating results.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other current financial metrics.
Material Changes
- Heng Fai Ambrose Chan resigned as a director effective June 6, 2024.
- The filing states that Mr. Chan’s resignation was not due to any disagreement with the company regarding its operations, policies, or practices.
- On June 6, 2024, the board appointed Jason T. Grady as a director, effective immediately.
Management Commentary, Risks, and Unusual Items
Mr. Grady serves in executive roles within DSS, Inc. and its subsidiaries and affiliates, including Chief Operating Officer of DSS, Inc., President of Premier Packaging Corporation, and President and COO of DSS Wealth Management and BioLife Science, Inc. The filing describes his experience in capital markets, mergers and acquisitions, corporate restructuring, packaging, pharmaceutical, biomedical, and nutraceutical businesses.
The filing states that there is no arrangement or understanding between Mr. Grady and any other person regarding his election, no family relationship with any director or executive officer, and no related-party transaction reportable under Item 404(a) of Regulation S-K.
Important Facts for Investors to Verify
- Confirm the current composition of the company’s board following Mr. Chan’s resignation and Mr. Grady’s appointment.
- Review subsequent filings for any additional information regarding Mr. Grady’s compensation, committee assignments, or related arrangements.
- Consult the company’s periodic reports for financial condition, liquidity, operating performance, and other investor-relevant metrics, which are not included in this filing.